Compare Omnicom Group Inc. (OMC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Repligen Corporation Common Stock — how do they compare? Omnicom Group Inc. trades at $78.92 (market cap $21.53B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 4.08% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 64 Days and Repligen Corporation Common Stock for 0 Days on average.
| OMC | RGEN | |
|---|---|---|
Market Cap | $21.53B | $11.14B |
Volume | 2,515,610 | 1,259,263 |
Sector | Media | Health |
52-Week High | $88.94 | $194.57 |
52-Week Low | $67.27 | $102.87 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | $29.61B | $11.02B |
Dividend Yield | 4.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $78.41, up 1.74% with a bullish technical signal despite mixed earnings results. The company shows strong revenue growth to $17.27B in 2025 but reported a net loss of -$54.50M. Analyst consensus is mixed with 32% buy ratings and a $100.50 price target, while recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings.
OMC presents a value opportunity with attractive P/S of 0.88 and dividend yield, though high P/E of 212.14 reflects earnings volatility. Key risks include advertising market weakness and elevated debt levels, while AI capabilities and post-Interpublic synergies offer growth catalysts for patient investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
